Shenzhen Kangtai Biological Products (, szse: 300601), also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.[1]
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China.[2][3][4]
References
- Shenzhen Kangtai Biological Products Co Ltd Bloomberg, retrieved 1 August 2021^
- Kangtai Biological's COVID-19 vaccine gets emergency use approval in China Reuters, 14 May 2021, retrieved 1 August 2021^
- AstraZeneca's China partner expects to be able to make 400 million COVID-19 vaccine doses a year Reuters, 2 February 2021, retrieved 1 August 2021^
- Scandal Dogs AstraZeneca's Vaccine Partner in China The New York Times, 7 January 2021, retrieved 1 August 2021^